Patent ID: 9566282
Date: 2017-02-14
CPC Classifications: A61K,A61P,C12Q,G01N

Claim:
1. A method for identifying and validating a test agent as a selective anti-cancer stem cell agent, the method comprising: i) contacting one or more variant neoplastic stem cells with the test agent and one or more normal stem cells with the test agent, wherein said variant neoplastic stem cells are transformed human Pluripotent Stem Cells or transformed induced Pluripotent Stem Cells characterized as having at least one property selected from ii) detecting a change in cell count of the variant neoplastic stem cells in response to the test agent, and detecting a change in cell count of the normal stem cells in response to the test agent; and iii) identifying the test agent as a selective anti-cancer stem cell agent if contact with the test agent induces a decrease in cell count of the variant neoplastic stem cells without inducing a comparable decrease in the normal stem cells; wherein the variant neoplastic stem cells are seeded in a first receptacle at about 3000 to 7000 cells per receptacle and the normal stem cells are seeded in a second receptacle at about 8000 to 12000 cells per receptacle.